T-cell therapy

- T-cell engager drugs have received FDA approval for small cell lung cancer, marking a significant advancement in solid tumor treatment.

The FDA has granted Breakthrough Therapy designation to Adaptimmune Therapeutics plc for its affinity enhanced T-cell therapy targeting NY-ESO in synovial sarcoma, highlighting the therapy's potential in treating this form of cancer. The designation is based on promising results from a phase I/II trial, showing significant response rates among patients.

- The FDA granted Breakthrough Therapy designation to Adaptimmune's affinity-enhanced T-cell therapy targeting NY-ESO for synovial sarcoma, expediting its development.